Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200503638> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W4200503638 endingPage "1234" @default.
- W4200503638 startingPage "1219" @default.
- W4200503638 abstract "Aims: To assess grade 3/4 adverse events (AEs) and costs of first-line nivolumab plus ipilimumab versus sunitinib in advanced or metastatic renal cell carcinoma. Methods: Individual patient data from the all treated population in the CheckMate 214 trial (nivolumab plus ipilimumab, n = 547; sunitinib, n = 535) were used to calculate the number of AEs. AE unit costs were obtained from US 2017 Healthcare Cost and Utilization Project and inflated to 2020 values. Results: The proportion of patients experiencing grade 3/4 AEs decreased over time. Patients who received nivolumab plus ipilimumab had lower average per-patient all-cause grade 3/4 AE costs versus sunitinib (12-month: US$15,170 vs US$20,342; 42-month: US$19,096 vs US$27,473). Conclusion: Treatment with nivolumab plus ipilimumab was associated with lower grade 3/4 AE costs than sunitinib.Immunotherapy combinations are now accepted as safe and effective first-line treatment options for advanced or metastatic renal cell carcinoma. This study used patient data from the CheckMate 214 clinical trial to evaluate the temporal trends and costs related to grade 3/4 adverse events (AEs) among patients treated with nivolumab plus ipilimumab versus sunitinib. We found that the proportion of patients experiencing grade 3/4 AEs decreased over time and that patients treated with nivolumab plus ipilimumab had lower AE costs compared with those treated with sunitinib (at 42 months: US$19,096 vs US$27,473 per patient). As such, nivolumab plus ipilimumab may represent a treatment option that may reduce both the clinical and economic burden among patients with advanced or metastatic renal cell carcinoma." @default.
- W4200503638 created "2021-12-31" @default.
- W4200503638 creator A5001763680 @default.
- W4200503638 creator A5025170069 @default.
- W4200503638 creator A5033372450 @default.
- W4200503638 creator A5065311807 @default.
- W4200503638 creator A5079623051 @default.
- W4200503638 creator A5082712288 @default.
- W4200503638 creator A5090867847 @default.
- W4200503638 date "2022-03-01" @default.
- W4200503638 modified "2023-10-03" @default.
- W4200503638 title "Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma" @default.
- W4200503638 cites W1964736588 @default.
- W4200503638 cites W2028424326 @default.
- W4200503638 cites W2057364180 @default.
- W4200503638 cites W2081390392 @default.
- W4200503638 cites W2092359522 @default.
- W4200503638 cites W2135139265 @default.
- W4200503638 cites W2139848613 @default.
- W4200503638 cites W2343255040 @default.
- W4200503638 cites W2610097533 @default.
- W4200503638 cites W2792937256 @default.
- W4200503638 cites W2886688315 @default.
- W4200503638 cites W2909056931 @default.
- W4200503638 cites W2911812451 @default.
- W4200503638 cites W2913500231 @default.
- W4200503638 cites W2913745075 @default.
- W4200503638 cites W2937867957 @default.
- W4200503638 cites W2938549381 @default.
- W4200503638 cites W2965207156 @default.
- W4200503638 cites W2967350775 @default.
- W4200503638 cites W3042095160 @default.
- W4200503638 cites W3056885861 @default.
- W4200503638 cites W3107453141 @default.
- W4200503638 cites W3131063362 @default.
- W4200503638 cites W3134949580 @default.
- W4200503638 cites W3172781556 @default.
- W4200503638 cites W3177754031 @default.
- W4200503638 cites W4237816489 @default.
- W4200503638 doi "https://doi.org/10.2217/fon-2021-1109" @default.
- W4200503638 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34939424" @default.
- W4200503638 hasPublicationYear "2022" @default.
- W4200503638 type Work @default.
- W4200503638 citedByCount "3" @default.
- W4200503638 countsByYear W42005036382022 @default.
- W4200503638 crossrefType "journal-article" @default.
- W4200503638 hasAuthorship W4200503638A5001763680 @default.
- W4200503638 hasAuthorship W4200503638A5025170069 @default.
- W4200503638 hasAuthorship W4200503638A5033372450 @default.
- W4200503638 hasAuthorship W4200503638A5065311807 @default.
- W4200503638 hasAuthorship W4200503638A5079623051 @default.
- W4200503638 hasAuthorship W4200503638A5082712288 @default.
- W4200503638 hasAuthorship W4200503638A5090867847 @default.
- W4200503638 hasBestOaLocation W42005036381 @default.
- W4200503638 hasConcept C121608353 @default.
- W4200503638 hasConcept C126322002 @default.
- W4200503638 hasConcept C143998085 @default.
- W4200503638 hasConcept C197934379 @default.
- W4200503638 hasConcept C2777472916 @default.
- W4200503638 hasConcept C2777701055 @default.
- W4200503638 hasConcept C2779490328 @default.
- W4200503638 hasConcept C2780030458 @default.
- W4200503638 hasConcept C2781433595 @default.
- W4200503638 hasConcept C2908647359 @default.
- W4200503638 hasConcept C71924100 @default.
- W4200503638 hasConcept C99454951 @default.
- W4200503638 hasConceptScore W4200503638C121608353 @default.
- W4200503638 hasConceptScore W4200503638C126322002 @default.
- W4200503638 hasConceptScore W4200503638C143998085 @default.
- W4200503638 hasConceptScore W4200503638C197934379 @default.
- W4200503638 hasConceptScore W4200503638C2777472916 @default.
- W4200503638 hasConceptScore W4200503638C2777701055 @default.
- W4200503638 hasConceptScore W4200503638C2779490328 @default.
- W4200503638 hasConceptScore W4200503638C2780030458 @default.
- W4200503638 hasConceptScore W4200503638C2781433595 @default.
- W4200503638 hasConceptScore W4200503638C2908647359 @default.
- W4200503638 hasConceptScore W4200503638C71924100 @default.
- W4200503638 hasConceptScore W4200503638C99454951 @default.
- W4200503638 hasIssue "10" @default.
- W4200503638 hasLocation W42005036381 @default.
- W4200503638 hasLocation W42005036382 @default.
- W4200503638 hasOpenAccess W4200503638 @default.
- W4200503638 hasPrimaryLocation W42005036381 @default.
- W4200503638 hasRelatedWork W2792937256 @default.
- W4200503638 hasRelatedWork W2890327592 @default.
- W4200503638 hasRelatedWork W2936603379 @default.
- W4200503638 hasRelatedWork W2981065291 @default.
- W4200503638 hasRelatedWork W3098031000 @default.
- W4200503638 hasRelatedWork W3152520552 @default.
- W4200503638 hasRelatedWork W3210028029 @default.
- W4200503638 hasRelatedWork W4200503638 @default.
- W4200503638 hasRelatedWork W4255880847 @default.
- W4200503638 hasRelatedWork W4362587156 @default.
- W4200503638 hasVolume "18" @default.
- W4200503638 isParatext "false" @default.
- W4200503638 isRetracted "false" @default.
- W4200503638 workType "article" @default.